Cite
HARVARD Citation
Swed, B. et al. (2021). Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma. Medicine. 100 (25), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Swed, B. et al. (2021). Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma. Medicine. 100 (25), p. . [Online].